HETERODIMERE VON GLUTAMINSÄURE

European patent · EP3335736 · Deleted

Register entry

Publication number: EP3335736
Application number: EP18150494
Kind: European patent with effect for Switzerland and Liechtenstein
Status: Deleted
Specification: Granted
Filed: Nov 7, 2007
Published: Jun 20, 2018
Granted: Dec 30, 2020
Deleted: Jun 30, 2022
Reason: Annual fee unpaid
IPC classes: A61K 51/00 (2006.01)
C07B 59/00 (2006.01)
C07C 275/16 (2006.01)
C07C 275/24 (2006.01)
C07C 275/30 (2006.01)
C07C 311/19 (2006.01)
C07D 213/38 (2006.01)
A61P 35/00 (2006.01)
A61K 39/385 (2006.01)
Priority: US 857490 P 08.11.2006
US 878678 P 05.01.2007
Filing language: English
Source: Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

Jun 30, 2022
Deleted, fee unpaid
Published in Swissreg on 30.06.2022
Jun 29, 2022
Change
Published in Swissreg on 29.06.2022
Feb 9, 2022
Change
Published in Swissreg on 09.02.2022
Oct 13, 2021
Change
Published in Swissreg on 13.10.2021
Oct 13, 2021
Change
Published in Swissreg on 13.10.2021
Oct 6, 2021
Change
Published in Swissreg on 06.10.2021
Feb 11, 2021
Owner
Owner
Molecular Insight Pharmaceuticals, Inc., 160 Second Street, Cambridge, MA 02142, USA → Molecular Insight Pharmaceuticals, Inc., One World Trade Center, 47th Floor, Suite J, New York, NY 10007, USA
Published in Swissreg on 11.02.2021
Dec 30, 2020
Granted
Published in Swissreg on 30.12.2020

Parties

Holder

Molecular Insight Pharmaceuticals, Inc.

One World Trade Center 47th Floor, Suite J, New York, NY 10007, US

Inventor

Maresca, Kevin P.

Tewksbury, MA 01876, US

Babich, John W.

New York, NY 10028, US

Zimmerman, Craig N.

Topsfield, MA 01983, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.